Pharmaceutical Technology

FEBRUARY 18, 2023

Novartis Overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. The company offers generic medicines and biosimilars through Sandoz.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Antibody Development 100

XTalks

DECEMBER 14, 2020

AvKARE, a generics pharmaceutical manufacturer based in Pulaski, Tennessee, has issued a recall on one lot each of its sildenafil 100 mg tablets and trazodone 100 mg tablets due to a packaging “mix-up” in which both drugs were filled into the same bottle. The identity of the facility was not disclosed.

Packaging 52

Packaging Packaging Drugs Generic Pharmaceutical 52

The Pharma Data

MAY 18, 2021

Sandoz to invest €150 million in new antibiotics manufacturing technology in Europe over next three to five years, to be optimally prepared for future needs. Kundl, Austria further strengthens production for oral antibiotics while facility in Palafolls, Spain expands for sterile active pharmaceutical ingredients. billion.

Manufacturing 40

Manufacturing Production Containment Generic Pharmaceutical 40

XTalks

JUNE 8, 2022

In a press release , the company says the goal of the Act4Biosimilars campaign is to help “address global health inequity and inequality” by increasing access to advanced medicines like biosimilars. This will be made achievable by improving the approvability, accessibility, acceptability and affordability (the 4 A’s) of biosimilars.

Generic Pharmaceutical 69

Generic Pharmaceutical Production Medicine Branding 69

The Pharma Data

JUNE 17, 2022

Sandoz, a global leader in generic and biosimilar medicines, today announced that the European Medicines Agency (EMA) has accepted the application for high concentration formulation 100 mg/mL (HCF) of its biosimilar Hyrimoz ® (adalimumab) for regulatory review. Source link: [link].

Medicine 52

Medicine Generic Pharmaceutical FDA Approval Packaging 52

The Pharma Data

MAY 2, 2021

With eight marketed biosimilar medicines globally and 15+ molecules in pipeline, Sandoz is investing in future of biosimilars for patients and healthcare systems. The study aims to confirm that the proposed biosimilar has equivalent efficacy and comparable safety to the reference medicine* in patients with nAMD 1. billion.

Clinical Development 40

Clinical Development Medicine Development Production 40

Pharmaceutical Technology

MARCH 22, 2023

In the 1990s, generic pharmaceutical companies in the European Union (EU) offshored the manufacturing of active pharmaceutical ingredients (API) primarily to China. Only 25% of API production for generic drugs took place in Europe in 2020, according to a November 2022 Medicines for Europe report.

Production 263

Production Manufacturing Drugs Generic Drugs 263

Pharmaceutical Technology

DECEMBER 22, 2022

This can include changes to materials and manufacturing, supply chain reviews; reduction in energy use or switches to renewables; recycling initiatives; and carbon offsetting. Blueprint Medicines wins the Financing award this year after securing significant financing partnerships worth up to $1.25bn. Innovation.

Insulin 130

Insulin Production Development Genetics 130

The Pharma Data

MAY 15, 2023

Shamiram holds an AB from Smith College and Doctor of Medicine as well as a Master of Public Health, both from Emory University, U.S.A. About Novartis Novartis is reimagining medicine to improve and extend people’s lives. Our ambition is to be the world’s leading and most valued generics company. billion.

Sales 40

Sales Production Doctors Doctor 40

XTalks

AUGUST 2, 2023

With each passing year, pharmaceutical companies around the globe strive to deliver cutting-edge medicines, therapies and vaccines that impact the lives of millions. is a global pharmaceutical company, working across both developed and emerging markets. billion the drug generated in 2021. billion in 2022, a 23.43

Sales 98

Sales Manufacturing FDA Approval Life Science 98

FDA Law Blog

JANUARY 24, 2024

is identified as “Improving Supply Chains for Critical Drugs,” and states: “ In 5 years, deploy broad synthetic biology and biomanufacturing capabilities to produce at least 25% of all active pharmaceutical ingredients (APIs) for small molecule drugs ” (emphasis added). generic pharmaceutical industry, resulting in low profit-margins.

Manufacturing 69

Manufacturing Drugs Generic Pharmaceutical Production 69